BR112020013820A2 - inibidores de pde10a para tratamento de sintomas negativos e comprometimentos cognitivos em um paciente sofrendo de esquizofrenia - Google Patents

inibidores de pde10a para tratamento de sintomas negativos e comprometimentos cognitivos em um paciente sofrendo de esquizofrenia Download PDF

Info

Publication number
BR112020013820A2
BR112020013820A2 BR112020013820-7A BR112020013820A BR112020013820A2 BR 112020013820 A2 BR112020013820 A2 BR 112020013820A2 BR 112020013820 A BR112020013820 A BR 112020013820A BR 112020013820 A2 BR112020013820 A2 BR 112020013820A2
Authority
BR
Brazil
Prior art keywords
pde10a inhibitor
pde10a
symptoms
negative symptoms
patient
Prior art date
Application number
BR112020013820-7A
Other languages
English (en)
Portuguese (pt)
Inventor
Jacob Nielsen
Raimund Buller
Original Assignee
H. Lundbeck A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H. Lundbeck A/S filed Critical H. Lundbeck A/S
Publication of BR112020013820A2 publication Critical patent/BR112020013820A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112020013820-7A 2018-11-06 2019-11-05 inibidores de pde10a para tratamento de sintomas negativos e comprometimentos cognitivos em um paciente sofrendo de esquizofrenia BR112020013820A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA201800825 2018-11-06
DKPA201800825 2018-11-06
EP19189762 2019-08-02
EP19189762.8 2019-08-02
PCT/EP2019/080151 WO2020094591A1 (fr) 2018-11-06 2019-11-05 Inhibiteurs de pde10a pour le traitement de symptômes négatifs et de troubles cognitifs chez un patient souffrant de schizophrénie

Publications (1)

Publication Number Publication Date
BR112020013820A2 true BR112020013820A2 (pt) 2021-06-01

Family

ID=68468731

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020013820-7A BR112020013820A2 (pt) 2018-11-06 2019-11-05 inibidores de pde10a para tratamento de sintomas negativos e comprometimentos cognitivos em um paciente sofrendo de esquizofrenia

Country Status (3)

Country Link
BR (1) BR112020013820A2 (fr)
TW (1) TW202031250A (fr)
WO (1) WO2020094591A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022060978A1 (fr) * 2020-09-16 2022-03-24 Matador Therapeutics, Inc. Méthodes de traitement de la maladie de parkinson et de troubles apparentés avec des inhibiteurs de pde10a

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1841757T3 (da) 2005-01-07 2010-09-13 Pfizer Prod Inc Heteroaromatiske quinolin-forbindelser og deres anvendelse som PDE10-hæmmere
TWI501965B (zh) 2008-06-20 2015-10-01 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物
SG171954A1 (en) 2008-12-04 2011-07-28 Hoffmann La Roche Pyridazinone derivatives
US8470820B2 (en) 2010-01-22 2013-06-25 Hoffman-La Roche Inc. Nitrogen-containing heteroaryl derivatives
US8410117B2 (en) 2010-03-26 2013-04-02 Hoffmann-La Roche Inc. Imidazopyrimidine derivatives
AU2011328598B2 (en) 2010-11-10 2016-04-21 H. Lundbeck A/S Radiolabelled phenylimidazole-based ligands
JO3089B1 (ar) 2010-11-19 2017-03-15 H Lundbeck As مشتقات ايميدازول كمثبطات لانزيمات pde10a
EP2574607A1 (fr) 2011-09-06 2013-04-03 F. Hoffmann-La Roche AG Modulateurs PDE10
CN104364249B (zh) 2012-05-30 2018-04-17 霍夫曼-拉罗奇有限公司 作为pde10抑制剂的三唑并化合物
CA2875057C (fr) 2012-07-09 2021-07-13 Janssen Pharmaceutica Nv Composes d'imidazo (1,2-b) pyridazine et d'imidazo (1,2-a) pyrazine et leur utilisation en tant qu'inhibiteurs de la phosphodiesterase 10
RU2015118286A (ru) 2012-11-07 2016-12-27 Ф. Хоффманн-Ля Рош Аг Соединения триазола
WO2015078836A1 (fr) 2013-11-28 2015-06-04 F. Hoffmann-La Roche Ag Dérivés d'imidazole

Also Published As

Publication number Publication date
TW202031250A (zh) 2020-09-01
WO2020094591A1 (fr) 2020-05-14

Similar Documents

Publication Publication Date Title
Pacifici Clinical pharmacology of midazolam in neonates and children: effect of disease—a review
Kapur et al. Methadone: a review of drug-drug and pathophysiological interactions
CA3079259A1 (fr) Ganaxolone destinee a etre utilisee dans le traitement de troubles epileptiques genetiques
JP7210564B2 (ja) カンナビジオールによる脆弱ｘ症候群の処置
JP2010510314A (ja) 精神遅滞、ダウン症候群、脆弱ｘ症候群および自閉症の治療方法
WO2012059526A1 (fr) Traitement de la mastocytose par le masitinib
US11826321B2 (en) Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions
EP3589369A1 (fr) Utilisation et composition pour traiter la myasthénie grave et d'autres syndromes myasthéniques
AU2024204179A1 (en) Compositions and method for treating depression
US20170119760A1 (en) Use of masitinib for the treatment of progressive supranuclear palsy
BR112020013820A2 (pt) inibidores de pde10a para tratamento de sintomas negativos e comprometimentos cognitivos em um paciente sofrendo de esquizofrenia
WO2023076404A1 (fr) Méthodes de traitement de lupus érythémateux disséminé
JP5299949B2 (ja) シロスタゾールの統合失調症治療剤
BR112020013697A2 (pt) compostos para tratamento de sintomas negativos e comprometimentos cognitivos
US11786507B2 (en) Methods of treating HIV-associated neurological disorders (HAND)
CN114901282B (zh) 在痴呆患者中治疗行为和精神症状
US20240358693A1 (en) Methods of treating pain
Messer et al. Neuropsychopharmacotherapy: Emergency Psychiatry
Shaw et al. Psychopharmacology in the physically ill child
Aronson Antipsychotic drugs
EA045669B1 (ru) Способы лечения поведенческих и психологических симптомов у пациентов с деменцией
Walsh Antihistamines (H1 receptor antagonists)
Ramos et al. Nonfatal suicidal olanzapine intoxication: a case report
US20170020867A1 (en) Use of masitinib for the treatment of crohn's disease
PRESCRIBED Change for

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 3A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2708 DE 29-11-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.